Through our broad approach to drugging the immune system, we have generated a robust pipeline focused on bridging innate and adaptive immunity.  Our differentiated antibodies and multispecifics effectively engage T cells and innate cells to promote tumor-specific activation or reverse immune suppression.


Partnering philosophy

We are looking for strategic partners to help advance our pipeline of next-generation antibody therapeutics. We are also seeking discovery collaborations around our StitchMabs™ and common light chain discovery technologies.

Are you interested in collaborating with us? Contact